ReviewBrain and behavior2023
Challenges and opportunities of diagnostic markers of Alzheimer's disease based on structural magnetic resonance imaging.
Review in Brain and behavior, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 19 citations in OpenAlex.
- Retinal proteomics in neurodegeneration: Insights into ocular and brain disorders.Neural regeneration research · 2026Article
- A new era of genome-wide association studies in the field of Alzheimer's disease and overlapping co-pathologies: lessons learned from a neuropathology-centered approach.Acta neuropathologica · 2026Review
- Enhanced monitoring of Alzheimer's disease brain atrophy using composite value ratios of volumes.Brain communications · 2026Article
- Agreement and Comparative Performance of Cognitive Testing, Visual MRI Rating, and Automated Brain Morphometry in Older Adults with Suspected Dementia in Uganda.Degenerative neurological and neuromuscular disease · 2026Article
- Novel multi-task learning for Alzheimer's stage classification using hippocampal MRI segmentation, feature fusion, and nomogram modeling.European journal of medical research · 2025Article
- Imaging markers of neuroinflammation in aging and Alzheimer's disease and related dementia: A comprehensive review.Neuroscience and biobehavioral reviews · 2025Review
- Exploring the neuromagnetic signatures of cognitive decline from mild cognitive impairment to Alzheimer's disease dementia.EBioMedicine · 2025Article
- Structural and microstructural changes in white and gray matter across the Alzheimer's disease continuum.Frontiers in aging neuroscience · 2025Review
- Machine Learning-Driven GLCM Analysis of Structural MRI for Alzheimer's Disease Diagnosis.Bioengineering (Basel, Switzerland) · 2024Article
- Alzheimer's disease pathophysiology in the Retina.Progress in retinal and eye research · 2024Review
- Review
- Challenges and opportunities of diagnostic markers of Alzheimer's disease based on structural magnetic resonance imaging.Brain and behavior · 2023Review
- Neuroimaging modalities in the detection of Alzheimer's disease-associated biomarkers.Psychoradiology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
objectivesThis article aimed to carry out a narrative literature review of early diagnostic markers of Alzheimer's disease (AD) based on both micro and macro levels of pathology, indicating the shortcomings of current biomarkers and proposing a novel biomarker of structural integrity that associates the hippocampus and adjacent ventricle together. This could help to reduce the influence of individual variety and improve the accuracy and validity of structural biomarker.
methodsThis review was based on presenting comprehensive background of early diagnostic markers of AD. We have compiled those markers into micro level and macro level, and discussed the advantages and disadvantages of them. Eventually the ratio of gray matter volume to ventricle volume was put forward.
resultsThe costly methodologies and related high patient burden of "micro" biomarkers (cerebrospinal fluid biomarkers) hinder the implementation in routine clinical examination. In terms of "macro" biomarkers- hippocampal volume (HV), there is a large variation of it among population, which undermines its validity Considering the gray matter atrophies while the adjacent ventricular volume enlarges, we assume the hippocampal to ventricle ratio (HVR) is a more reliable marker than HV alone the emerging evidence showed hippocampal to ventricle ratio predicts memory functions better than HV alone in elderly sample.
conclusionsThe ratio between gray matter structures and adjacent ventricular volumes counts as a promising superior diagnostic marker of early neurodegeneration.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.